Sector News

Roche to sell U.S. plant to Patheon, saving about 200 jobs

November 29, 2016
Life sciences

Roche has a deal to sell an API plant in South Carolina to CDMO Patheon for a nominal amount, a deal that will save about 200 jobs at the plant in Florence which the Swiss drugmaker was preparing to close.

Durham, NC-based Patheon said it has a definitive agreement to buy the 1,100-acre, 300,000-square-foot facility for what it said is an “immaterial sum, plus the cost of associated inventory and spare parts.”

It also has a multiyear year deal to supply Roche with APIs that will help cover the costs of the facility until the contractor can get new business into it. Patheon said the facility will expand its capacity for manufacturing highly potent compounds, while adding micronization capabilities and commercial spray drying.

“The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals,” Patheon CEO James Mullen said in a statement.

In an emailed statement, Roche spokeswomen Anja von Treskow said Tuesday the deal with Patheon, which is already a supplier to Roche, is expected to close within 60 days.

Roche said last year it would close the Florence plant, along with plants in Clarecastle, Ireland; Leganes, Spain, and Segrate, Italy, as part of a cost-saving plan that would remove about 1,200 jobs from its payroll. It took a charge of about $1.6 billion for the closures.

While its decision was firm, the Swiss drugmaker said it was trying to sell the plants to save jobs. In June, Greek contract manufacturer Famar said it had struck a deal to take the Leganes, Spain, plant and to supply Roche with APIs.

“In regards to the other sites, we can confirm that we are continuing with our efforts to divest Leganés and Segrate as operational sites to a reputable company, while Clarecastle is in the process of ramping down with production estimated to end in 2019. At this point in time we cannot comment further,” Roche said in its statement.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.